STAT6 Small-Molecule Modulators for Oral and Topical Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective, orally available modulators of STAT6, and there is a need for small molecule inhibitors suitable for both systemic and topical administration to treat STAT6-associated diseases, particularly those involving Th2-mediated inflammation and cancer.
Innovation Solution
Development of novel azaindoles and their derivatives that exhibit high metabolic stability, membrane permeability, and solubility, enabling oral and topical administration to modulate STAT6 signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies targeting Th2 immune responses (such as dupilumab, tralokinumab) are used, then efficacy in Th2-driven diseases is achieved, but administration route is limited to injection and device complexity increases
Solution Approach 1:
The patent replaces the mechanical injection system with a small molecule compound that can be administered orally or topically. The small molecule STAT6 inhibitor substitutes the antibody-based biologic therapy, eliminating the need for injection devices and complex administration protocols while maintaining therapeutic efficacy in Th2-driven diseases.
2Ease of operation
If small molecule STAT6 inhibitors are developed for oral administration, then ease of operation is improved, but metabolic stability and membrane permeability requirements increase device complexity
Solution Approach 1:
The patent optimizes the chemical parameters of the small molecule compound, specifically adjusting metabolic stability and membrane permeability properties. By modifying the molecular structure of the STAT6 inhibitor to enhance these parameters, the compound achieves oral bioavailability without requiring complex delivery systems or formulation technologies.
3Loss of substance
If topical administration is used for localized treatment, then loss of substance is reduced, but achieving sufficient penetration and efficacy becomes more difficult
Solution Approach 1:
The patent applies local quality by using topical administration of the small molecule STAT6 inhibitor to deliver therapy directly to the affected skin areas. The compound's optimized membrane permeability enables sufficient penetration through the skin barrier to reach target cells locally, providing therapeutic efficacy while minimizing systemic exposure and reducing loss of substance.
Data Source
AI summary
The present disclosure relates to a compound according to formula (I)and pharmaceutically acceptable salts, hydrates, or solvates thereof. The disclosure further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.